Replimune Group, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
FDA granted accelerated approval on August 6, 2026 for TUDRIQEV (vusolimogene oderparepvec-wtpg) combined with nivolumab for unresectable advanced cutaneous melanoma progressing after anti-PD-1 therapy. In the IGNYTE trial (n=91 efficacy-evaluable), the combination achieved 24.2% objective response rate with 14.1-month median duration of response; adverse events were predominantly grade 1–2. Approval is conditioned on confirmatory Phase 3 IGNYTE-3 trial completion. Company targets ~10,000 addressable U.S. patients and plans commercial launch with manufacturing facility to ship product within ~60 days.
Why this rating
First approved product for ~$235M biotech validates platform; addresses large unmet need (10K patients); meaningful revenue upside, but approval is accelerated, contingent on Phase 3 confirmation.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.